Literature DB >> 6681959

The inhibition of hepatic S-3-hydroxy-3-methylglutaryl-CoA reductase by 3,3,5-trimethylcyclohexanol and its mandelic acid ester, cyclandelate.

B Middleton, A Middleton, A Miciak, D A White, G D Bell.   

Abstract

Rat hepatic HMGCoA reductase was found to be at least 50% inhibited 17 hr after administration of a single oral dose of 3,3,5-trimethylcyclohexanyl mandelate (cyclandelate), a vasoactive substance. This inhibition was also found in rats given the 3,3,5-trimethylcyclohexanol component but only slight inhibition was seen after an equimolar dose of mandelate. The inhibition of HMGCoA was observed both around the high point and near the low point of the diurnal activity cycle. The effect did not persist to 41 hr after treatment. There was no direct inhibition of HMGCoA reductase by trimethylcyclohexanol when added to the assay system in vitro. The in vivo effect of these inhibitors was specific for HMGCoA reductase. There was no change, neither elevation nor depression, of the amount of microsomal membrane components cytochromes b5 and P-450, not was the activity of another microsomal enzyme, arylesterase, affected by dosing with cyclandelate or trimethylcyclohexanol.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6681959     DOI: 10.1016/0006-2952(83)90489-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  The effect of cyclandelate on cholesterol metabolism in patients with familial hypercholesterolaemia.

Authors:  J A Gevers Leuven; H vd Voort; H J Kempen; E de Wit; L Havekes
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Cyclandelate. An inhibitor of cholesterol esterification.

Authors:  B Middleton; F Cacciaguerra; D White
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Cyclandelate versus flunarizine. A double-blind study in a selected group of patients with dementia.

Authors:  M G Albizzati; S Bassi; E Calloni; M Sbacchi; R Piolti; L Frattola
Journal:  Drugs       Date:  1987       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.